{"id":"https://openalex.org/W2279855182","doi":"https://doi.org/10.1016/s0022-3565(25)09636-3","title":"Imidazenil, a new anxiolytic and anticonvulsant drug, attenuates a benzodiazepine-induced cognition deficit in monkeys.","display_name":"Imidazenil, a new anxiolytic and anticonvulsant drug, attenuates a benzodiazepine-induced cognition deficit in monkeys.","publication_year":1995,"publication_date":"1995-06-01","ids":{"openalex":"https://openalex.org/W2279855182","doi":"https://doi.org/10.1016/s0022-3565(25)09636-3","mag":"2279855182","pmid":"https://pubmed.ncbi.nlm.nih.gov/7791102"},"language":"en","primary_location":{"id":"doi:10.1016/s0022-3565(25)09636-3","doi":"https://doi.org/10.1016/s0022-3565(25)09636-3","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0022-3565(25)09636-3","pdf_url":null,"source":{"id":"https://openalex.org/S102125482","display_name":"Journal of Pharmacology and Experimental Therapeutics","issn_l":"0022-3565","issn":["0022-3565","1521-0103"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310316283","host_organization_name":"American Society for Pharmacology and Experimental Therapeutics","host_organization_lineage":["https://openalex.org/P4310316283"],"host_organization_lineage_names":["American Society for Pharmacology and Experimental Therapeutics"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Pharmacology and Experimental Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109984316","display_name":"Donald M. Thompson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I125043107","display_name":"Nathan Kline Institute for Psychiatric Research","ror":"https://ror.org/01s434164","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I125043107"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D M Thompson","raw_affiliation_strings":["Center for Neuropharmacology, Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Neuropharmacology, Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, USA","institution_ids":["https://openalex.org/I125043107"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090826335","display_name":"James Auta","orcid":"https://orcid.org/0000-0002-5468-7704","observed_orcids":["https://orcid.org/0000-0002-5468-7704"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J Auta","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048825104","display_name":"Alessandro Guidotti","orcid":"https://orcid.org/0000-0003-4480-0010","observed_orcids":["https://orcid.org/0000-0003-4480-0010"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A Guidotti","raw_affiliation_strings":["Psychiatry"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Psychiatry","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5051515082","display_name":"E. Costa","orcid":"https://orcid.org/0000-0003-0792-5439","observed_orcids":["https://orcid.org/0000-0003-0792-5439"]},"institutions":[{"id":"https://openalex.org/I125043107","display_name":"Nathan Kline Institute for Psychiatric Research","ror":"https://ror.org/01s434164","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I125043107"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E Costa","raw_affiliation_strings":["NATHAN S. KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NATHAN S. KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH","institution_ids":["https://openalex.org/I125043107"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3750,"currency":"USD","value_usd":3750},"apc_paid":null,"fwci":0.902,"has_fulltext":false,"cited_by_count":24,"citation_normalized_percentile":{"value":0.70911437,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"273","issue":"3","first_page":"1307","last_page":"1312"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.8672000169754028,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.8672000169754028,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.03229999914765358,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12229","display_name":"Pharmacological Effects and Toxicity Studies","score":0.02280000038444996,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alprazolam","display_name":"alprazolam","score":0.9729999899864197},{"id":"https://openalex.org/keywords/anxiolytic-effects","display_name":"anxiolytic effects","score":0.7250000238418579},{"id":"https://openalex.org/keywords/anticonvulsant-activity","display_name":"anticonvulsant activity","score":0.9900000095367432},{"id":"https://openalex.org/keywords/learning-deficits","display_name":"learning deficits","score":0.4440000057220459},{"id":"https://openalex.org/keywords/response-errors","display_name":"response errors","score":0.3160000145435333},{"id":"https://openalex.org/keywords/fixed-ratio-schedules","display_name":"fixed-ratio schedules","score":0.6000000238418579},{"id":"https://openalex.org/keywords/patas-monkey","display_name":"patas monkey","score":0.4449999928474426}],"concepts":[{"id":"https://openalex.org/C2777196872","wikidata":"https://www.wikidata.org/wiki/Q319877","display_name":"Alprazolam","level":3,"score":0.9483712911605835},{"id":"https://openalex.org/C2777765862","wikidata":"https://www.wikidata.org/wiki/Q62903","display_name":"Anxiolytic","level":3,"score":0.6971097588539124},{"id":"https://openalex.org/C2778173252","wikidata":"https://www.wikidata.org/wiki/Q83871","display_name":"Benzodiazepine","level":3,"score":0.6958454847335815},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6887048482894897},{"id":"https://openalex.org/C2775858608","wikidata":"https://www.wikidata.org/wiki/Q576618","display_name":"Anticonvulsant","level":3,"score":0.5821136236190796},{"id":"https://openalex.org/C168258287","wikidata":"https://www.wikidata.org/wiki/Q60147","display_name":"GABAA receptor","level":3,"score":0.4727172255516052},{"id":"https://openalex.org/C2776239663","wikidata":"https://www.wikidata.org/wiki/Q742487","display_name":"Nootropic","level":2,"score":0.4642323851585388},{"id":"https://openalex.org/C2776814716","wikidata":"https://www.wikidata.org/wiki/Q574801","display_name":"Sedation","level":2,"score":0.45697033405303955},{"id":"https://openalex.org/C2776175493","wikidata":"https://www.wikidata.org/wiki/Q210402","display_name":"Diazepam","level":2,"score":0.4558890461921692},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.4228157699108124},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3771008253097534},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.30774492025375366},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.3070976138114929},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3048078417778015},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.29435837268829346},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.18447807431221008},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.17397606372833252},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000525","descriptor_name":"Alprazolam","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000927","descriptor_name":"Anticonvulsants","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001569","descriptor_name":"Benzodiazepines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003072","descriptor_name":"Cognition Disorders","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D003072","descriptor_name":"Cognition Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004901","descriptor_name":"Erythrocebus patas","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014151","descriptor_name":"Anti-Anxiety Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D018757","descriptor_name":"GABA Modulators","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1016/s0022-3565(25)09636-3","doi":"https://doi.org/10.1016/s0022-3565(25)09636-3","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0022-3565(25)09636-3","pdf_url":null,"source":{"id":"https://openalex.org/S102125482","display_name":"Journal of Pharmacology and Experimental Therapeutics","issn_l":"0022-3565","issn":["0022-3565","1521-0103"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310316283","host_organization_name":"American Society for Pharmacology and Experimental Therapeutics","host_organization_lineage":["https://openalex.org/P4310316283"],"host_organization_lineage_names":["American Society for Pharmacology and Experimental Therapeutics"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Pharmacology and Experimental Therapeutics","raw_type":"journal-article"},{"id":"pmid:7791102","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7791102","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of pharmacology and experimental therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.832.4216","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.832.4216","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://jpet.aspetjournals.org/content/273/3/1307.full.pdf","raw_type":"text"},{"id":"mag:2279855182","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/7791102","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8999999761581421}],"study_designs":[],"awards":[{"id":"https://openalex.org/G170313486","display_name":null,"funder_award_id":"R01MH49486-03","funder_id":"https://openalex.org/F4320337346","funder_display_name":"National Institute of Mental Health"},{"id":"https://openalex.org/G902826492","display_name":"PHARMACOLOGY--ALLOSTERIC MODULATORS OF GABAA RECEPTORS","funder_award_id":"R01MH049486","funder_id":"https://openalex.org/F4320337346","funder_display_name":"National Institute of Mental Health"}],"funders":[{"id":"https://openalex.org/F4320337346","display_name":"National Institute of Mental Health","ror":"https://ror.org/04xeg9z08"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7100457244","https://openalex.org/W2011493516","https://openalex.org/W1971336985","https://openalex.org/W2030448540","https://openalex.org/W1919267946","https://openalex.org/W2252747350","https://openalex.org/W2089700993","https://openalex.org/W2024364948","https://openalex.org/W2090470362","https://openalex.org/W2008627941"],"abstract_inverted_index":null,"counts_by_year":[{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}